Cite
HARVARD Citation
Gao, J. et al. (2020). CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet oncology. 21 (2), pp. 250-260. [Online].